Ketek Act I: FDA Updates Label, Touts Process On Eve Of Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency says it has “learned” from controversy surrounding the antibiotic, but FDA will likely still face congressional grilling about its actions.
You may also be interested in...
Antibiotics Legislation Could Boost Confidence Of Sponsors And FDA Alike
A limited population antibacterial drug pathway could reassure investors about the viability of antibiotics and help FDA avoid looking over its shoulder as it approves products based on limited data, though enactment is uncertain.
House Panel May Subpoena FDA Investigators To Address Ketek Safety Study
Agency foot-dragging over questions regarding approval of the Sanofi-Aventis antibiotic leads House Energy and Commerce subcommittee to consider forcing testimony.
House Panel May Subpoena FDA Investigators To Address Ketek Safety Study
Agency foot-dragging over questions regarding approval of the Sanofi-Aventis antibiotic leads House Energy and Commerce subcommittee to consider forcing testimony.